Catalog No.
YHE58701
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Arg22-Gln138
Predicted molecular weight
15.88 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P48546
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Gastric inhibitory polypeptide receptor, GIP-R, Glucose-dependent insulinotropic polypeptide receptor, GIPR
Designing structure-specific and switchable allosteric effectors for GPCRs based on the causality and energetics of inherent signaling., PMID:40513649
Differential Role of Phosphorylation in Glucagon Family Receptor Signaling Revealed by Mass Spectrometry., PMID:40503712
De novo design of miniprotein agonists and antagonists targeting G protein-coupled receptors., PMID:40501737
Contractile effects of retatrutide in isolated mouse atrial preparations., PMID:40464942
Molecular Design of Unimolecular Tetra-Receptor Agonists., PMID:40461942
Design of potent and proteolytically stable double biaryl-stapled GLP-1R/GIPR peptide dual agonists., PMID:40311601
GIPR-Ab/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice., PMID:40301582
Tirzepatide increased force of contraction in the isolated human atrium., PMID:40299022
Targeted intervention in obesity-associated atrial fibrosis using nanoparticle-loaded fusion protein., PMID:40281309
Secretory stimuli distinctly regulate insulin secretory granule maturation through structural remodeling., PMID:40235991
Penta-ALFA-Tagged Substrates for Self-Labelling Tags Allow Signal Enhancement in Microscopy., PMID:40222732
Identification of anti-resorptive GPCRs by high-content imaging in human osteoclasts., PMID:40215127
Incretin-based therapeutics for the treatment of neurodegenerative diseases., PMID:40211045
The C-terminal regions of the GLP-1 and GIP receptors are not the key determinants of their differential arrestin recruitment but modulate the rate of receptor endocytosis., PMID:40201698
The role of GIPR in food intake control., PMID:40166681
MIR192 Upregulates GLP-1 Receptor and Improves Statin-Induced Impairment of Insulin Secretion., PMID:40166140
A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans., PMID:40139439
Development of a long-acting unbiased GIP receptor agonist for studies of GIP's role in bone metabolism., PMID:40132763
The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose Metabolism., PMID:40125821
Glucose-dependent insulinotropic polypeptide (GIP)., PMID:40024571
Single incretin receptor knockout mice do not compensate by increasing glucose-stimulated secretion of the remaining incretin hormone., PMID:39933706
D-Ala2-GIP (1-30) promotes angiogenesis by facilitating endothelial cell migration via the Epac/Rap1/Cdc42 signaling pathway., PMID:39855534
The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP-1/GIP receptor agonist (BGM0504) in healthy volunteers: A dose-escalation Phase I study., PMID:39840511
Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation., PMID:39788289
The other side of the incretin story: GIPR signaling in energy homeostasis., PMID:39778517
SNPs in GPCR Genes and Impaired Osteogenic Potency in Osteoporotic Patient Lines-Based Study., PMID:39769358
Glucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in mice., PMID:39723966
GLP-1R/NPY2R regulate gene expression, ovarian and adrenal morphology in HFD mice., PMID:39692365
Treatment with sitagliptin exacerbates the M2 phenotype in macrophages in vitro., PMID:39662268
The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice., PMID:39642881
Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss., PMID:39612941
Red and far-red cleavable fluorescent dyes for self-labelling enzyme protein tagging and interrogation of GPCR co-internalization., PMID:39610654
GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells., PMID:39607493
Endogenous Glucagon-Like Peptide-1 Receptor and Glucose-Dependent Insulinotropic Polypeptide Receptor Signaling Inhibits Aeroallergen-Induced Innate Airway Inflammation., PMID:39559998
Incretin-responsive human pancreatic adipose tissue organoids: A functional model for fatty pancreas research., PMID:39549913
Genetic Evidence for GLP-1 and GIP Receptors as Targets for Treatment and Prevention of MASLD/MASH., PMID:39487684
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors., PMID:39326429
Lead-in calorie restriction enhances the weight-lowering efficacy of incretin hormone-based pharmacotherapies in mice., PMID:39265725
Insights into the structure and activation mechanism of some class B1 GPCR family members., PMID:39240462
Glucose-dependent insulinotropic polypeptide (GIP) alleviates ferroptosis in aging-induced brain damage through the Epac/Rap1 signaling pathway., PMID:39219045
The unexpected role of GIP in transforming obesity treatment., PMID:39198118
New insights into the regulation of GIPR signalling., PMID:39174673
GIP Receptor Antagonism Eliminates Paradoxical Growth Hormone Secretion in Some Patients With Acromegaly., PMID:39172542
Primary unilateral macronodular adrenal hyperplasia with concomitant glucocorticoid and androgen excess and KDM1A inactivation., PMID:39171930
Potent and Protease Resistant Azapeptide Agonists of the GLP-1 and GIP Receptors., PMID:39151024
Isoquinoline small molecule ligands are agonists and probe-dependent allosteric modulators of the glucagon subfamily of GPCRs., PMID:39147328
AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys., PMID:39128651
Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration., PMID:39062586
Therapeutic potentials of glucose-dependent insulinotropic polypeptide (GIP) in T2DM: Past, present, and future., PMID:39059989
From the First Case Reports to KDM1A Identification: 35 Years of Food (GIP)-Dependent Cushing's Syndrome., PMID:39059410
For research use only. Not for human or drug use.
